+1-888-308-5802     
News Contact Us

Pharma giant Pfizer to acquire Array BioPharma valued at $11.4 billion

Author : Paroma Bhattacharya | Published Date : 2019-06-19 

Pfizer Inc., the New York-based pharmaceutical multinational, has reportedly announced that it will acquire Array BioPharma Inc., a commercial stage company focused on the discovery, development and commercialization of small molecule medicines to treat cancer and other crucial diseases.

As per trusted sources, Pfizer is paying $48 per share in cash to Array and the total valuation of the deal is estimated at $11.4 billion.

Albert Bourla, CEO, Pfizer was reportedly quoted stating that the merger reinforces the company’s commitment to change the lives of the patients while creating strong shareholder value. The acquisition of Array BioPharma strengthens Pfizer’s biopharmaceutical business and will also enhance the long-term goals of the company while creating an industry leading firm for colorectal cancer along with focusing on the current expertise in prostate and breast cancer, he further added.

For the record, Array’s portfolio includes the approved combined use of MEKTOVI (binimetinib) and BRAFTOVI (encorafenib) for the treatment of BRAF V600E or BRAF V600K mutant unresectable or metastatic melanoma. The combination of these drugs has a significant potential for long term expansion into areas of undiscovered treatment for crucial diseases. These are being investigated in over 30 clinical laboratories across solid tumor indications which include the Phase 3 BEACON trial in BRAF mutant metastatic colorectal cancer (MCRC).

In 2018, 140,250 patients were diagnosed with colon or rectum cancer in the U.S., making it the third most common type of cancer in the country. BRAF mutations apparently occur in more than 15% of colorectal cancer and approximately 50,000 of the diagnosed patients die every year.

Ron Squarer, CEO, Array, reportedly stated that the merger of the companies will bring about great discoveries in the biopharma field and extend the lives of the patients. Array will gain access to a broader research platform and world-class resources by way of its merger with Pfizer which would help the company to continue developing even more options for individuals with unmet needs, Squarer added.

Reportedly, Pfizer is expected to complete the deal in the second half of 2019.

 

Sources: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_array_biopharma

https://www.moneycontrol.com/news/world/pfizer-makes-10-6-billion-cancer-bet-in-cash-deal-for-array-biopharma-4108861.html

About Author

Paroma Bhattacharya

Paroma Bhattacharya

Paroma Bhattacharya, having completed her post-graduation in Journalism and Mass Communication, started her career in writing with resourceful and informative content development across diverse fields. Having dealt in myriad topics ranging from business to real estate, she now pens down articles for fractovia.org and other portals. She can be contacted at- [email protected] | https://twitter.com/paromab1

Related News

iPR Software launches new AI-based software dubbed ‘Metatron’

Published Date: 2019-10-21         Author: Paroma Bhattacharya

Artificial Intelligence (AI) is becoming a vital part of user’s daily life, right from satellite imagery to Google assistant. Speculating the potential of AI, companies are increasing integrating this technology in their new upcoming platforms and software. iPR Software has made a similar d... Read More

Gurugram-based Cars24 raises $100Mn in a Series D funding round

Published Date: 2019-10-18         Author: Paroma Bhattacharya

India’s used-car market has become one bright spot especially since the recent slowdown that impacted the country’s automobile industry. Online market platforms play a vital role in bringing used cars closer to customers. Sellers meanwhile demand transparency in business, ease of underst... Read More

IMS subsidiary rolls out blockchain-powered organic platform in China

Published Date: 2019-10-15         Author: Paroma Bhattacharya

A booming middle-class population in China along with changing consumer outlook towards heathy lifestyle indicates immense potential for the organic market in the region to grow. Analysts claim that China’s middle class will account for more than one-third of its population by 2030 which will ... Read More

© 2019 Fractovia. All Rights Reserved